You are here:Home-Community manager
Community manager

About Community manager

This author has not yet filled in any details.
So far Community manager has created 124 blog entries.

Survey

Do you want us to host Q&A sessions for webinars you've missed? With this survey we would like to evaluate the audience interest in additional Q&A sessions for our previous webinars. We are considering to arrange live webinars where we replay the recording of the presentation of previous webinars and then host another live Q&A session with the speaker on the line. We will look specifically into the need for such Q&A webinars at times that allow people in

Survey2020-02-11T10:26:56+00:00

The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study

Speakers: Anand Anandkumar, Co-founder and CEO Bugworks Research Inc (India) Kamini Walia, Program Officer, ICMR-AMR Initiative (India)  Moderator: François Franceschi, GARDP  The presentation will be followed by a Q&A session. Register now for this live webinar including interactive Q&A session on 5 May 2020, 9:00-10:30 am CEST (find your time zone here). If you have questions or comments, please let us know. Do so by submitting them via the 'Talk to an expert' feature or contact us by email:

The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study2020-02-12T09:20:53+00:00


Diagnostics to safeguard new and current antibiotics for gonorrhoea
– by Cassandra Kelly-Cirino and Cecilia Ferreyra

Gonorrhoea and chlamydia are the two most common sexually transmitted infections (STIs) in the world, with a staggering 214 million new cases occurring in 2016 alone.1 While anyone having unprotected sex is at risk, both diseases disproportionately affect sex workers and their clients, and men who have sex with men. Today, we have the means to treat both diseases, but the emergence of so-called ‘super-gonorrhoea’ is of great concern in the global battle against antimicrobial resistance. At the heart


Diagnostics to safeguard new and current antibiotics for gonorrhoea
– by Cassandra Kelly-Cirino and Cecilia Ferreyra
2020-01-22T07:45:57+00:00

Non-traditional antibacterial therapeutic options and challenges

Speaker: Ursula Theuretzbacher, CEFAIA (Austria) Moderator: Prabhavathi Fernandes, Chair of GARDP's Scientific Advisory Committee (USA) In this webinar, Ursula Theuretzbacher discussed the following aspects of non-traditional antibacterial therapeutics: Discovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline These approaches include anti-virulence strategies, microbiome-modifying therapies, phages and others such as nanoparticles, immunotherapy and drug-resistance modulation. Some of these approaches require novel preclinical efficacy models to predict clinical outcome Pathogen-specific or even patient-specific

Non-traditional antibacterial therapeutic options and challenges2020-02-05T13:33:15+00:00

Testing for the potential of emergence of antimicrobial resistance

Speaker: Michael Mourez, Head BacteriOmics Platform, Evotec, France Moderator: Laura Piddock, Director Scientific Affairs, GARDP In this webinar, the following aspects were presented: What are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques? What are some techniques that may be used to understand the origins of resistance selection? How to rationalize/manage the risk of translation of

Testing for the potential of emergence of antimicrobial resistance2020-01-22T15:33:25+00:00


On fireworks and finding ways to address drug-resistance in low- and middle-income countries
– by Ramanan Laxminarayan

Every autumn the Diwali festival is celebrated with food, gifts and fireworks. Ramanan Laxminarayan, Chair of the Board of the Global Antibiotic Research and Development Partnership (GARDP) reflects on India’s efforts to reduce fireworks-related injuries, and what lessons can be applied to the efforts to address antibiotic resistance. I was recently asked if I thought behaviour change around antibiotics was possible, particularly in low- and middle-income countries (LMICs), which have historically had limited controls around the use of these


On fireworks and finding ways to address drug-resistance in low- and middle-income countries
– by Ramanan Laxminarayan
2019-12-17T13:11:14+00:00

Bootcamp: Post-Approval Economics for New Antibiotics (ASM/ESCMID 2019)

Antibiotic Bootcamps for Developers: Post-Approval Economics for New Antibiotics ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 3-6 September 2019, Boston Collaboratively organized by GARDP, CARB-X, REPAIR Impact Fund, JPIMAR and Wellcome Trust Moderator: Ryan Cirz Speakers: Kevin Krause (AN2 Therapeutics, U.S. and formerly Achaogen), Craig Lichtenstein (Sana Biotechnology, U.S. and formerly Achaogen), Rolf Wagenaar (CD&E Consulting LLC, U.S.) Q&A session: Kevin Krause (AN2 Therapeutics, U.S. and formerly Achaogen), Craig Lichtenstein (Sana Biotechnology, U.S. and

Bootcamp: Post-Approval Economics for New Antibiotics (ASM/ESCMID 2019)2019-11-29T13:11:04+00:00

Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process (ASM/ESCMID 2019)

Antibiotic Bootcamps for Developers: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 3-6 September 2019, Boston Collaboratively organized by GARDP, CARB-X, REPAIR Impact Fund, JPIAMR and Wellcome Trust Moderator: Ursula Theuretzbacher (Center for Anti-Infective Agents, Austria) Speakers: Michael Mourez (Evotec, France), Douglas Huseby (University Uppsala, Sweden) Q&A session: Michael Mourez (Evotec, France), Douglas Huseby (University Uppsala, Sweden), Mariana Castanheira (JMI Laboratories, U.S.), Ursula Theuretzbacher (Center

Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process (ASM/ESCMID 2019)2020-01-20T08:43:32+00:00


Talking about the ‘antibiotic apocalypse’ won’t encourage public action – here’s why
– by Tim Jinks

Antimicrobial resistance has a language problem, and we’ve known it for a while. Back in 2015, Wellcome published research revealing that people in the UK have little awareness of the issue and how it could affect their health – mainly because of the way it’s talked about. Since then we’ve been using the term ‘drug-resistant infections’ for our public-facing communications which, according to our research, people find more accessible than ‘antimicrobial’ or ‘antibiotic resistance’. Even so, we know that


Talking about the ‘antibiotic apocalypse’ won’t encourage public action – here’s why
– by Tim Jinks
2019-11-19T07:40:17+00:00


A new cephalosporin has been approved
– by Ursula Theuretzbacher

After approval of four new ß-lactamase inhibitor (BLI) combinations in the last five years, a new member of the ß-lactam class made it to the finish line. On November 14, 2019 the US Food and Drug Administration (FDA) approved cefiderocol (Fetroja) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by susceptible Gram-negative bacteria, in patients with limited or no alternative treatment options. What makes this new antibiotic special? Cefiderocol is the first new cephalosporin since


A new cephalosporin has been approved
– by Ursula Theuretzbacher
2019-11-18T13:29:34+00:00

Innovation in point-of-care diagnostics for sepsis and bloodstream infections

Download the speakers' slides here! Speakers: Till Bachmann, University of Edinburgh, UK Amrita Sukrity, SpotSense, India David Anderson, Burnet Institute, Australia Moderator: Caroline Purslow, Nesta Challenges In this webinar our moderator Caroline Purslow (Nesta Challenges) welcomed three speakers. Till Bachmann gave an overview of recent advances in AMR diagnostics development. He discussed: State of the art approaches for diagnosing infections and AMR Pipeline of promising tests Challenges of adoption Amrita Sukrity drew from her experience as a founder

Innovation in point-of-care diagnostics for sepsis and bloodstream infections2019-12-04T14:41:28+00:00


Lessons from a recent outbreak of carbapenem-resistant Klebsiella pneumoniae in a neonatal unit
– by Adrie Bekker

Our hospital is a tertiary referral centre in South Africa that manages up to 8000 high-risk deliveries per year of which 45% of newborns are of low birth weight (< 2500 grams). The neonatal unit has > 100 beds available to care for sick newborns (four wards and eight neonatal intensive care beds) and is mostly at full capacity. Prior to December 2018, we had only seen one case of bacteraemia caused by carbapenem-resistant Klebsiella pneumoniae, which belong to


Lessons from a recent outbreak of carbapenem-resistant Klebsiella pneumoniae in a neonatal unit
– by Adrie Bekker
2019-10-28T12:54:53+00:00

Structure Activity Relationships and Additivity — Going Beyond Conventional Wisdom

On 19 September, CDD will host a webinar about Structure Activity Relationships and Additivity. Drs. James “Guy” Breitenbucher and Peter Gedeck will talk about what’s new with theory, experiments, and technologies for better understanding SAR and additivity (and non-additivity). The discussion will focus on: Where SAR broke the traditional additivity rules What frameworks are most practical for understanding different types of underlying SAR patterns New technologies to more rapidly traverse SAR fragment lattices just invented To register for this

Structure Activity Relationships and Additivity — Going Beyond Conventional Wisdom2019-09-10T11:40:54+00:00

Converting Gram-positive-only compounds into broad-spectrum antibiotics

Speaker: Paul Hergenrother, Kenneth L. Rinehart Endowed Chair in Natural Products Chemistry, Department of Chemistry and the Institute for Genomic Biology, University of Illinois, US Moderator: Laura Piddock, Director of Scientific Affairs, GARDP In this webinar, Paul detailed his research group's efforts to understand compound accumulation in the Gram-negative ESKAPE pathogens. Emphasis was placed on the practicality, actionability, and translatability of this information, specifically, the use of accumulation rules to convert high-value Gram-positive-only compounds into antibiotics with activity against

Converting Gram-positive-only compounds into broad-spectrum antibiotics2019-11-08T15:36:09+00:00


Journey towards a better antimicrobial pipeline; is there light at the end of the tunnel?
– by Colm Leonard & Tracy Parker

The Global Action Plan on antimicrobial resistance (AMR), endorsed at the World Health Assembly in May 2015, recognised the need for sustainable and increased investment in new medicines, diagnostic tools, vaccines and other interventions. In 2016, the global facing independent review on AMR, led by Lord O’Neill, recommended a global system of market entry rewards. This was also recognised by the G20 leaders’ statement in 2017 which committed to exploring practical market incentive options. Many other governments and international


Journey towards a better antimicrobial pipeline; is there light at the end of the tunnel?
– by Colm Leonard & Tracy Parker
2019-09-02T07:32:41+00:00

Natural product antibiotics: from traditional screening to novel discovery approaches

Speaker: Olga Genilloud, Scientific Director, Fundación MEDINA, Granada, Spain Moderator: Laura Piddock, Director of Scientific Affairs, GARDP In this webinar, Olga Genilloud discussed the role of natural products in current antibiotic discovery. Topics included: Screening strategies to identify novel antibiotics Current challenges and novel analytical tools New omic approaches supporting antibiotic discovery The presentation was followed by a Q&A session. This live webinar including interactive Q&A session was broadcast on 3 October 2019. If you have questions or comments,

Natural product antibiotics: from traditional screening to novel discovery approaches2019-10-04T12:21:16+00:00

Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research

Speaker: Peter Warn, Senior Vice President, Anti-infective Discovery, Evotec Moderator: William J. Weiss, Director, PreClinical Services, University of North Texas System College of Pharmacy In this webinar, Peter Warn reviewed the experimental design and conduct of advanced or complex animal models for antimicrobial research. This webinar is designed as a follow on from the webinar of William J. Weiss: Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research. Topics covered in this webinar

Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research2019-09-13T09:52:24+00:00


Addressing Gram-negative permeation & efflux evasion with a collaborative discovery tool
– by Wes Kim & Katie Prosen

The antibiotics pipeline is insufficient to address the growing public health threat posed by Gram-negative ESKAPE pathogens—which are among the hardest to treat—and by other antibiotic-resistant bacteria. Of the 42 antibiotics currently in development, only 16 have the potential to target Gram-negative pathogens, and only one of those represents a novel class, according to an analysis by The Pew Charitable Trusts. To stay ahead of resistance, more novel antibiotics targeting Gram-negative bacteria are needed. The brain drain associated with


Addressing Gram-negative permeation & efflux evasion with a collaborative discovery tool
– by Wes Kim & Katie Prosen
2019-07-24T08:35:14+00:00

Enabling Academia to Fill the Discovery Gap

Meet-the-experts session (S386): 'Enabling Academia to Fill the Discovery Gap ' ASM Microbe, 24 June 2019, San Francisco Learnings from Industry and Funders Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria Bridging the Gap: NIAID Resources to Facilitate Discovery and Development of Anti-Infectives Robin Broughton, NIAID/NIH, Rockville, MD Find all details here to join us at this session! Jointly organized with:                  

Enabling Academia to Fill the Discovery Gap2019-06-07T09:12:03+00:00

Better Science Through Metadata

On 13 June, CDD will host a webinar about the importance of metadata to increase reproducibility and productivity across the scientific community. Speakers: Ellen L. Berg, Chief Scientific Officer, Translational Biology for Eurofins Discovery Isabella Feierberg, Associate Principal Scientist, AstraZeneca To register for this webinar, please visit the CDD website.

Better Science Through Metadata2019-06-07T08:39:58+00:00

Models for antimicrobial R&D:
Computational modelling for population PK and PKPD

Speakers: Lena Friberg & Elisabet Nielsen, Department of Pharmaceutical Biosciences, Uppsala University, Sweden Moderator: Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria In this webinar, Lena Friberg and Elisabet Nielsen discussed: Population PK modelling to characterize drug exposure and variability PKPD-modelling to characterize preclinical time-kill data PKPD-modelling for translation to patients Model-based dose-individualization This live webinar including interactive Q&A session was broadcast on 20 August 2019. If you have questions or comments, please let us know. Do so by

Models for antimicrobial R&D:
Computational modelling for population PK and PKPD
2019-08-23T07:49:49+00:00

CARB-X 2019 Funding Rounds Webinar

Thursday, May 16, 2019 03:00 PM CEST - 04:00 PM CEST Kevin Outterson, CARB-X Executive Director, and Karen Gallant, CARB-X Global R&D Project Director, present details of CARB-X’s four new funding rounds announced April 30, 2019, and answer questions during this webinar. To attend the live webinar, please register by completing the form on the right. Find more information and a registration link here. A recording of the webinar will be available for viewing shortly after the event.

CARB-X 2019 Funding Rounds Webinar2019-05-14T09:19:31+00:00

Enabling academia to fill the discovery gap – Learnings from industry and funders

Speaker: Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria Moderator: Laura Piddock, Director Scientific Affairs, GARDP In this webinar, Ursula Theuretzbacher discussed why small companies and academic labs are currently the main drivers of antibiotic R&D and what challenges they face. Topics discussed included: Mainly small companies are active in antibacterial drug R&D and pursue a variety of approaches Main challenges of various antibacterial R&D approaches What to learn from industry and funders How to avoid the most common mistakes

Enabling academia to fill the discovery gap – Learnings from industry and funders2019-08-23T08:03:04+00:00

Infection models for antimicrobial R&D: Intracellular models

Speaker: Françoise van Bambeke, Research Director Cellular and Molecular Pharmacology, Louvain Drug Research Institute, Université catholique de Louvain (Belgium) Moderator: Laura Piddock, Director of Scientific Affairs, GARDP In this webinar, Françoise van Bambeke talked about intracellular activity of antibiotics. Topics discussed included: The role of intracellular survival in chronic infections and its contribution to poor response to antibiotics In vitro models to study intracellular activity of antibiotics Cellular pharmacokinetic (PK) parameters predictive of intracellular potency for antibiotics Cellular pharmacodynamics

Infection models for antimicrobial R&D: Intracellular models2019-08-23T08:01:46+00:00

Find out how GARDP is redoubling its efforts to accelerate the development and delivery of new and improved antibiotics

Speaker: Manica Balasegaram, Executive Director, GARDP Moderator: Jennifer Katz, Director of External Affairs, GARDP In this webinar, Dr Manica Balasegaram, GARDP’s Executive Director highlighted GARDP’s role in accelerating the implementation of WHO’s Global Action Plan, and share GARDP’s updated strategy. This live webinar including interactive Q&A session was broadcast on 26 June 2019. If you have questions or comments, please let us know: revive@gardp.org.

Find out how GARDP is redoubling its efforts to accelerate the development and delivery of new and improved antibiotics2019-07-11T07:46:30+00:00

New initiatives to support AMR innovation (BSAC Spring Conference 2019)

BSAC Spring Conference 2019: Global views, local problems: Innovative solutions to AMR and infection challenges 21 – 22 March 2019, International Convention Centre, Birmingham, UK Parallel session one 'New initiatives to support AMR innovation' co-developed by GARDP and CARB-X Public health driven R&D of antibiotics for priority drug resistant infections Dr Seamus O'Brien, R&D Director, Global Antibiotic R&D Partnership (GARDP) CARB-X: Building A Portfolio of New Antibiotics, Vaccines & Diagnostics with Open Science Dr Richard

New initiatives to support AMR innovation (BSAC Spring Conference 2019)2019-06-07T09:16:01+00:00

Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research

Speaker: William J. Weiss, Director, PreClinical Services, University of North Texas System College of Pharmacy Moderator: Peter Warn, Senior Vice President, Anti-infective Discovery, Evotec In this webinar, William J. Weiss introduced experimental design of animal models for antimicrobial research. He discussed questions such as: Where to start and what model to use? Are animal models of bacterial infection reflective of the clinical condition? Are in vivo animal model results predictive of clinical efficacy? This webinar including interactive Q&A session

Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research2019-08-23T08:00:09+00:00

Mining Chemical Libraries for New Antibacterials – Session 2

In this webinar, the recording of Carl Balibar's presentation 'Mining of chemical libraries for new antibacterials' (original webinar on 21 May) was followed by another live Q&A session with Carl. Speaker: Carl Balibar, Principal Scientist, Merck Research Laboratories Moderator: Benjamin Blasco, Discovery Senior Project Manager, GARDP Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening

Mining Chemical Libraries for New Antibacterials – Session 22019-08-23T07:58:38+00:00

Resistance testing – beyond serial passage experiments

Pre-conference workshop: 'Resistance testing – beyond serial passage experiments' 12th Berlin Conference on Life Sciences - Novel Antimicrobials & AMR Diagnostics, 14-15 March 2019, Berlin Emergence of mutational resistance - Threat or myth? Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria Testing of dual/multiple target drugs Michael Mourez, Evotec ID Lyon, France Testing of single target drugs Diarmaid Hughes, Uppsala University & ENABLE, Sweden Jointly organized with:                  

Resistance testing – beyond serial passage experiments2019-04-08T12:19:43+00:00


How to steward new antibiotics into low- and middle-income countries (LMICs)?
– by Marc Mendelson & Adrian Brink

Despite the many health system challenges faced by resource-poor LMICs, access to new antibiotics used in the treatment of multi-drug resistant (MDR) and extensively-drug resistant (XDR) bacterial infections should be a fundamental right, which must be achieved in order to ensure equity in clinical management of bacterial infection for a global community. Historically this has not been achieved, but rather populations in high income countries have benefitted, first and foremost. This basic right will need to be enabled by


How to steward new antibiotics into low- and middle-income countries (LMICs)?
– by Marc Mendelson & Adrian Brink
2019-07-24T08:35:41+00:00

Mining Chemical Libraries for New Antibacterials

Speaker: Carl Balibar, Principal Scientist, Merck Research Laboratories Moderator: Benjamin Blasco, Discovery Senior Project Manager, GARDP Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening remains the primary source for new antibacterial compounds, which mainly come from mining various chemical libraries. In this webinar, Carl Balibar (Merck Research Laboratories) discussed screen design, target bias, and

Mining Chemical Libraries for New Antibacterials2019-07-11T07:48:26+00:00


The REPAIR Impact Fund: Reflections from the first year
– by Aleks Engel

Antimicrobial resistance (AMR) is a massive and growing concern worldwide. What can stop it? It is a complex and far-reaching problem with no easy answers, but we are trying to take important first steps. The REPAIR Impact Fund was launched on the 28th of February 2018. With the first year behind us, I reflect on some surprising lessons learned, thoughts about the future, and finally a more personal perspective. As one of the largest dedicated for-profit life science investors,


The REPAIR Impact Fund: Reflections from the first year
– by Aleks Engel
2019-03-01T11:47:01+00:00


Turning the tide on R&D – WHO launches first data call to review pre-clinical pipeline to tackle antibiotic resistance
– by Sarah Paulin and Peter Beyer

The R&D pipeline for new antibacterials to treat increasingly resistant bacterial infections is virtually dry. Very few classes of new antibiotics in particular to treat Gram-negatives have come to the market since the “golden age” of antibiotic discovery. The World Health Organization’s (WHO) global analysis of the clinical pipeline against the priority pathogens in 2017 and 2018 showed that the current pipeline is not very promising to keep up with the evolving resistant bacterial infections with only one of


Turning the tide on R&D – WHO launches first data call to review pre-clinical pipeline to tackle antibiotic resistance
– by Sarah Paulin and Peter Beyer
2019-03-14T14:18:43+00:00


Time to pull out all the stops in the fight against superbugs
– by Kevin Outterson

Great progress on push incentives In the Review on Antimicrobial Resistance (AMR), Lord Jim O’Neill called for a Global AMR Fund with $2 billion over five years. In the past few years, we have seen impressive efforts of new initiatives for research against drug-resistant infections, starting with BARDA, NIAID, Wellcome Trust, JPIAMR, and ND4BB’s ENABLE and TRANSLOCATION projects. In 2016, CARB-X was launched to fund and support innovative early development, GARDP joined the team as a developer, and 2018 saw


Time to pull out all the stops in the fight against superbugs
– by Kevin Outterson
2019-03-01T11:48:35+00:00


Antibacterial drugs: Clinical development for non-developers
Part 3: Non-traditional approaches

Moderator: David Shlaes, Anti-infectives consulting, retired Speakers: Ian Friedland, Clinical consultant, Friedland Strategic Consulting, LLC Sumathi Nambiar, Director, Division of Anti-Infective Products, Office of Antimicrobial Products, CDER, FDA Mair Powell, Senior Clinical Assessor, Health Products Regulatory Authority (Ireland) The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches (Tiers A and B),


Antibacterial drugs: Clinical development for non-developers
Part 3: Non-traditional approaches
2019-08-23T08:06:49+00:00


NIAID Resources to Facilitate Discovery & Development
of Anti-Infectives

NEW: Download a summary of this webinar here! Speakers: Ann Eakin, Senior Scientific Officer Office of Biodefense, Research Resources & Translational Research, DMID/NIAID/NIH Dan Pevear, Sr. Vice President, Biology and Grants Development, VenatoRx Pharmaceuticals Incorporated Moderator: François Franceschi, Project leader AMREP, GARDP In this webinar, Ann Eakin (US National Institute of Allergy and Infectious Diseases, NIAID) provided an overview of the various mechanisms of support offered by NIAID to facilitate the discovery and development of drugs, vaccines and diagnostics


NIAID Resources to Facilitate Discovery & Development
of Anti-Infectives
2019-08-23T08:08:05+00:00


Why we need to prioritize developing antibiotics for children
– by Manica Balasegaram

A question I’m frequently asked is “with the rise of drug-resistant infections, how does GARDP decide where to focus its efforts”? It’s a reasonable question. And our approach is simple. We consider the priority pathogens identified by World Health Organization (WHO), but also consider the needs and gaps for diseases and key populations when defining which antibiotics to develop. In this way, our efforts focus on global public health priorities and indications less likely to be developed by others.


Why we need to prioritize developing antibiotics for children
– by Manica Balasegaram
2019-04-30T13:14:16+00:00

BSAC Antimicrobial Chemotherapy Conference 2019

Antimicrobial Chemotherapy Conference 2019 - An ABC for Everyone Involved in Developing New Antimicrobials 15 January 2019, London Organized by the British Society for Antimicrobial Chemotherapy (BSAC) in collaboration with GARDP Session 1: Antimicrobial drug discovery - an essential overview Opening Remarks Laura Piddock, Head of Scientific Affairs, Global Antibiotic R&D Partnership (GARDP) The risks of clinical development from the perspective of the antibacterial discovery scientist David Shlaes, Former Professor of Medicine, Case Western Reserve University,

BSAC Antimicrobial Chemotherapy Conference 20192019-02-15T09:34:14+00:00

CARB-X: Combating Antibiotic Resistance Globally Webinar

On 15 January 2019, Professor Kevin Outterson, executive director of CARB-X, will be featured in a webinar to introduce and explain the public-private partnership CARB-X, which is dedicated to the early development of innovative antibiotics, vaccines, and other products to fight superbugs. Find more information and a registration link here.

CARB-X: Combating Antibiotic Resistance Globally Webinar2019-01-11T15:19:20+00:00


Recent approvals – do they make a difference?
– by Ursula Theuretzbacher

Six new antibiotics have been approved by the U.S. Food and Drug Administration (FDA) over the last four years. So, at a first glance it seems that there is renewed interest in developing new antibiotics against Gram-negative pathogens. Nevertheless, all six antibiotics – ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, plazomicin, eravacycline, and omadacycline are improved derivatives of well-known antibiotic classes to address class-specific resistance mechanisms. Five of these antibiotics have been developed against infections mainly caused by Gram-negative pathogens, omadacycline, a tetracyline


Recent approvals – do they make a difference?
– by Ursula Theuretzbacher
2019-03-01T11:49:29+00:00

New Strategies in Antibiotic Drug Development

On December 13th, 2018, Collaborative Drug Discovery (CDD) will host a webinar on New Strategies in Antibiotic Drug Development with Dr. Arthur “AJ” Campbell & Dr. Cheryl Quinn. The talk is hosted by CDD, in conjunction with Pew Trusts and moderated by Keystone Symposia CSO Dr. Thale Jarvis with an introduction from Dr. Wes Kim, Senior Officer of Pew Trust's Antibiotic Resistance Project. The discussion will be highly informed with a focus on: How we can move the needle

New Strategies in Antibiotic Drug Development2019-01-11T15:20:58+00:00

Stemming the Superbug Tide: Just a Few Dollars More – Looking at the New OECD Report on AMR

On 11 December, 14:00 GMT, the Leading Health System Network (LHSN), a collaborative network of healthcare leaders and organisations, will host a webinar discussing the OECD report ‘Stemming the Superbug Tide: Just a Few Dollars More’. This report describes the long-term public health and economics consequences of the rise in AMR and identifies effective solutions to tackle this top public health priority. For more information visit the LHSN website.

Stemming the Superbug Tide: Just a Few Dollars More – Looking at the New OECD Report on AMR2019-01-11T15:21:15+00:00


More than one model to stimulate antimicrobial drug development
– by Jim O’Neill

When I first started leading the AMR Review in 2014, I soon came to the conclusion that, if the current model wasn’t delivering new antimicrobial drugs, the solution was obvious: launch a new public purpose-focused entity dedicated to developing and producing new antimicrobials. When I shared this hunch with others, I was advised that it couldn’t be done without the major pharmaceutical companies, as they were the only ones with the expertise to produce and distribute drugs. I let this


More than one model to stimulate antimicrobial drug development
– by Jim O’Neill
2019-03-01T11:50:18+00:00

The AMR Studio – A podcast by the Uppsala Antibiotic Center

The Uppsala Antibiotic Center launches their newest outreach project, "The AMR Studio", with the occasion of the World Antibiotic Awareness Week 2018. The AMR Studio is a podcast dedicated to highlighting the multidisciplinary research on antimicrobial resistance that is happening around the world. Formatted around interviews with professionals working in all aspects of the topic, they aim to bring the global and trans-sectorial nature of the fight against antimicrobial and antibiotic resistance to anyone with an interest. In

The AMR Studio – A podcast by the Uppsala Antibiotic Center2019-01-11T15:21:59+00:00

External blogs in the field

The views and opinions expressed in this blog are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contributors. GARDP is not responsible for the content of external sites. John H. Rex: Solutions for Antimicrobial Resistance David Shlaes: Antibiotics - The Perfect Storm Longitude Prize - Blog The Center For Disease Dynamics, Economics & Policy (CDDEP)

External blogs in the field2019-03-01T11:51:02+00:00

Making Safety a Part of Drug Design

Speaker: Claire Sadler, Senior Toxicologist, ApconiX, UK Moderator: Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria * This presentation was also part of the GARDP and CARB-X co-organized session 'Antibiotic Bootcamps for Developers: Preclinical Toxicology' at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance * In this webinar, Claire Sadler discussed the toxicological challenges and pitfalls of antibiotic discovery programs. Potential safety risks are the major reason for terminating a program in early phases of antibiotic

Making Safety a Part of Drug Design2019-08-23T08:10:33+00:00

Bootcamp: Preclinical Toxicology (ESCMID/ASM 2018)

Antibiotic Bootcamps for Developers: Preclinical Toxicology ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 4-7 September 2018, Lisbon A collaborative project of GARDP and CARB-X Chair person: Ursula Theuretzbacher Speakers: Terry Miller, Claire Sadler, Ryan Cirz Roundtable discussion: Terry Miller, Claire Sadler, Ryan Cirz, Ursula Theuretzbacher Introduction Pitfalls in Preclinical Development from the Regulatory Perspective (FDA) (Terry Miller) Making Safety a Part of Drug Design (Claire Sadler) Real life story of unexpected toxicity - Lessons to

Bootcamp: Preclinical Toxicology (ESCMID/ASM 2018)2019-01-07T09:18:26+00:00

FDA’s Plan to Combat Antibiotic Resistance

On Friday, Sept. 14, 2018, at 10 a.m. EDT, The Pew Charitable Trusts hosts Dr. Scott Gottlieb, commissioner of the U.S. Food and Drug Administration, as he announces the agency’s plans to combat antibiotic resistance. Following Gottlieb’s remarks, a panel of FDA senior officials will further explore the agency’s new and ongoing activities to support antibiotic innovation and ensure that antimicrobial drugs are used according to good stewardship practices in human medicine and animal agriculture. Click here to

FDA’s Plan to Combat Antibiotic Resistance2019-01-11T15:22:18+00:00

A Discussion with Chris Lipinski and Barry Bunin

On September 13th, 2018, Collaborative Drug Discovery (CDD) will host a webinar with Christopher Lipinski and Barry Bunin. The discussed topics will include: Going beyond the Rules of 5 New technologies to better assess the quality of screening data Experimental culture and sociology as a factor in clustering of results Plus topics you would not expect, like how scientists can (and should) respond to the growing opioid addiction crisis – which has actually lowered life expectancy in America

A Discussion with Chris Lipinski and Barry Bunin2019-01-11T15:22:38+00:00

Bootcamp: Medicinal Chemistry (ESCMID/ASM 2018)

Antibiotic Bootcamps for Developers: Medicinal Chemistry ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 4-7 September 2018, Lisbon A collaborative project of GARDP and CARB-X Chair persons: John Griffin and Heinz Moser Speakers: Andrea Decker, Heinz Moser, John Griffin Roundtable discussion: Andrea Decker, Heinz Moser, John Griffin, John H. Rex Introduction Drug-Likeness: Physicochemical Properties in Small-Molecule Drug Discovery (Andrea Decker) Drug Discovery of Antibiotics: The Importance of Physicochemical Properties (Heinz Moser) Emerging Artificial Intelligence Approaches in

Bootcamp: Medicinal Chemistry (ESCMID/ASM 2018)2019-01-07T09:19:00+00:00


Antibacterial drugs: Clinical development for non-developers
Part 2: Development of antibacterial drugs targeting specific pathogens

Moderator: David Shlaes, Anti-infectives consulting, retired Speakers: Ian Friedland, Clinical consultant, Friedland Strategic Consulting, LLC Sumathi Nambiar, Director, Division of Anti-Infective Products, Office of Antimicrobial Products, CDER, FDA Mair Powell, Senior Clinical Assessor, Licensing Division, Medicines and Healthcare products Regulatory Agency (UK) The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches


Antibacterial drugs: Clinical development for non-developers
Part 2: Development of antibacterial drugs targeting specific pathogens
2019-08-23T08:11:49+00:00

Battle of the Bugs: Designing the Best Approach in the Fight Against Infectious Disease

Webinar on models for drug development programmes by Charles River: The emergence of antibiotic-resistant bacteria and genetic variance amongst viruses has embattled the development of effective treatment and vaccination against infectious diseases, leading to a worldwide crisis in medical care. This webinar will help you choose the correct models for your drug development program; from early in vitro screening assays providing identification of efficacy, to a range of clinically relevant in vivo models. We also explore the use

Battle of the Bugs: Designing the Best Approach in the Fight Against Infectious Disease2019-06-07T08:48:12+00:00

PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?

Speaker: William Hope, Centre of Antimicrobial Pharmacodynamics, University of Liverpool Moderator: Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria * This presentation was also part of the GARDP and CARB-X co-organized session 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th ECCMID in Madrid in April 2018. * In this webinar, William Hope talked about the role of pharmacokinetics and pharmacodynamics for antimicrobial drug development. He discussed the EMA guideline on the use

PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?2019-08-23T08:12:51+00:00


Antibacterial drugs: Clinical development for non-developers
Part 1: Traditional development – tiers A and B

NEW: Download a summary of this webinar here! Speaker: David Shlaes - Anti-infectives consulting, retired Moderator: Laura Piddock - Head of Scientific Affairs, GARDP In this presentation we introduce the relationship between the discovery phase and later clinical development. We discuss in some depth traditional clinical development pathways (tiers A and B) focusing on the non-inferiority trial design. We hosted this live webinar with David Shlaes and Laura Piddock on June 13, 2018. If you have questions or comments,


Antibacterial drugs: Clinical development for non-developers
Part 1: Traditional development – tiers A and B
2019-08-23T08:13:49+00:00

Drug Discovery Data Insights: Highly Accessible SAR Data is Transforming the Drug Discovery Informatics Landscape

On June 26th, 2018, Collaborative Drug Discovery (CDD) hosted a webinar where moderator Ashley Farley, Associate Officer of Knowledge & Research Services at the Bill & Melinda Gates Foundation (BMGF) discussed drug discovery data with Dr. Andrew Leach from ChEMBL and Dr. Evan Bolton from PubChem. The presenters discussed the emergence of freely available PubChem and ChEMBL resources for chemical and biological Structure-Activity-Relationship (SAR) data and their impact on the global drug discovery informatics landscape. The relationship between

Drug Discovery Data Insights: Highly Accessible SAR Data is Transforming the Drug Discovery Informatics Landscape2019-01-11T15:25:30+00:00

Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?

John H. Rex Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed

Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?2019-01-07T09:20:25+00:00

PK-PD in support of accelerated programmes: how much is enough?

William Hope Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up

PK-PD in support of accelerated programmes: how much is enough?2019-01-07T09:20:41+00:00

US regulatory tools for expedited antibacterial development programmes

Sumathi Nambiar Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up

US regulatory tools for expedited antibacterial development programmes2019-01-07T09:20:56+00:00